TransMedics Announces the Presentation of New OCS™ Heart and OCS™ Lung Clinical Data at the International Society of Heart and Lung Transplantation 2022 Annual Meeting

Rhea-AI Summary

TransMedics Group announces the presentation of new clinical data from its OCS™ Heart and Lung trials at the ISHLT 2022 Annual Meeting, scheduled for April 27-30, 2022, in Boston, MA. Key presentations include long-term results from the OCS DCD Heart trial and the OCS Lung EXPAND trial. These findings may significantly impact organ transplant therapy for patients with end-stage organ failure. TransMedics is set to host a symposium featuring global transplant leaders discussing their experiences with the OCS technology.

Positive

• Presentation of long-term results from OCS DCD Heart trial, which could enhance heart transplantation protocols.
• Showcasing OCS Lung EXPAND trial results, indicating improved outcomes for lung transplant patients.
• Opportunity to interact with transplant leaders at the symposium, which may foster collaborations and partnerships.

Negative

• None.

ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that new clinical data from its OCS™ Heart and OCS™ Lung clinical trials will be presented at the upcoming International Society of Heart and Lung Transplantation (ISHLT) 2022 Annual Meeting taking place April 27-30, 2022 in Boston, MA. The Company will also host a symposium and display its OCS™ technology at booth #419 at the conference.

"We have several seminal clinical readouts for OCS Heart and Lung technologies at this year's ISHLT scientific meeting.  We are thrilled to unveil the full data and long-term results of our OCS DCD Heart trial results, the OCS Heart EXPAND trial two-year follow up data benchmarked against standard criteria hearts, and the OCS Lung EXPAND trial long-term outcome data at ISHLT 2022," said Waleed Hassanein, MD, President and Chief Executive Officer. "We are also looking forward to hosting our annual State-of-the Art Symposium featuring transplant leaders from all over the world presenting their experience with the OCS Lung and Heart technology platform."

Featured Presentations:
Title:	Long-term Results of the OCS Lung Expand International Trial Using Organ Care System Lung Perfusion System (OCS) in Extended-Criteria Donor (ECD) and Donation After Circulatory Death (DCD) Donor Lungs
Presenter:	Gabriel Loor, MD., Surgical Director, Lung Transplant - Baylor St. Luke's Medical Center, Houston TX
Date/Time:	Thursday, April 28th at 11:45 a.m. ET
Title:	Expanding Heart Transplants from Donors After Circulatory Death (DCD) – Results of the First Randomized Controlled Trial Using the Organ Care System (OCS™) Heart – (OCS DCD Heart Trial)
Presenter:	Jacob Schroder, MD., Assistant Professor of Surgery – Duke University Medical Center, Durham, NC
Date/Time:	Friday, April 29th at 8:30 a.m. ET
Title:	Increasing Utilization of Extended Criteria Donor After Brain Death (DBD) Hearts Seldomly Used for Transplantation in the U.S. Due to Limitation of Ischemic Cold Storage - 2-Year Results of the OCS Heart EXPAND Prospective Multi-Center Trial (OCS Heart EXPAND)
Presenter:	Jacob Schroder, MD., Assistant Professor of Surgery – Duke University Medical Center, Durham, NC
Date/Time:	Friday, April 29th at 9:00 a.m. ET

Symposium Information:
TransMedics will also host a symposium, titled "TransMedics Organ Care System (OCS™): State of the Art Heart and Lung Extracorporeal Perfusion & Assessment Symposium – The New Frontiers", on Thursday, April 28^th at 12:15 p.m. at the Hynes Convention Center, Room 208.

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-announces-the-presentation-of-new-ocs-heart-and-ocs-lung-clinical-data-at-the-international-society-of-heart-and-lung-transplantation-2022-annual-meeting-301528269.html

SOURCE TransMedics Group, Inc.

FAQ

What are the key findings presented by TransMedics at the ISHLT 2022 Annual Meeting?

TransMedics presented long-term results from the OCS DCD Heart trial and the OCS Lung EXPAND trial, which could significantly enhance transplant outcomes.

When and where will the ISHLT 2022 Annual Meeting take place?

The ISHLT 2022 Annual Meeting will occur from April 27-30, 2022, in Boston, MA.

What technology is TransMedics showcasing at the ISHLT 2022 Annual Meeting?

TransMedics is showcasing its OCS™ technology, which focuses on organ perfusion and assessment for transplantation.

What is the significance of the clinical trials being presented by TransMedics?

The trials potentially improve organ transplant protocols, offering better outcomes for patients with end-stage organ failure.

What is the symposium hosted by TransMedics about?

The symposium titled 'TransMedics Organ Care System (OCS™): State of the Art Heart and Lung Extracorporeal Perfusion & Assessment Symposium' discusses advancements in organ transplantation.